Presentados en ASH los datos de un estudio de Fase III que evalan REVLIMID en pacientes con mieloma indolente de alto riesgo

Show Health and Fitness Publications

Thu, December 15, 2011

[ Thu, Dec 15th 2011 ]: Market Wire

Arrowhead to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results

[ Thu, Dec 15th 2011 ]: Market Wire

Covidien plant Ausgliederung des Unternehmensbereichs Pharmazeutika

[ Thu, Dec 15th 2011 ]: Market Wire

Covidien envisage une scission de sa branche Pharmacie

[ Thu, Dec 15th 2011 ]: Market Wire

Soligenix Initiates Next Generation Anthrax Vacci .. t Program Under Agreement With Harvard University

[ Thu, Dec 15th 2011 ]: Market Wire

SciClone Pharmaceuticals Announces Final Settlement of Stockholder Derivative Litigation

[ Thu, Dec 15th 2011 ]: Market Wire

Importante grupo cooperativo de investigacin sobr .. elige REVLIMID para el estudio del segundo subtip

[ Thu, Dec 15th 2011 ]: Market Wire

Perceptive Informatics Completes Over 500 System .. Industry Continues to Adopt Seamless eClinical S

[ Thu, Dec 15th 2011 ]: Market Wire

Illumina Hires Laura Lauman as Vice President of Marketing

Wed, December 14, 2011

[ Wed, Dec 14th 2011 ]: Market Wire

Lilly Recognized as One of the Best Places to Work for LGBT Equality

[ Wed, Dec 14th 2011 ]: Market Wire

Amica Mature Lifestyles Announces Closing of Subs .. cluding Exercise in Full of Over-Allotment Option

[ Wed, Dec 14th 2011 ]: Market Wire

Amgen Announces Final Results of Its Tender Offer

[ Wed, Dec 14th 2011 ]: Market Wire

Tortoise Pipeline & Energy Fund Announces Full Investment and Top Ten Holdings

[ Wed, Dec 14th 2011 ]: Market Wire

Pfizer, Cisco, Walt Disney, Research In Motion, U .. ban Outfitters and Green Mountain Coffee Roasters

[ Wed, Dec 14th 2011 ]: Market Wire

A Change in Tides - Featured Research on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)

[ Wed, Dec 14th 2011 ]: Market Wire

St. Jude Medical annuncia il primo impianto nella .. clinica per la valutazione dalla valvola cardiac

[ Wed, Dec 14th 2011 ]: Market Wire

CytoSorbents Awarded US Army SBIR Trauma Grant

[ Wed, Dec 14th 2011 ]: Market Wire

IntegraMed America Selects Adaptive Planning

[ Wed, Dec 14th 2011 ]: Market Wire

Definitieve fase 2 gegevens van evaluatie REVLIMI .. et recidiverende of refractaire chronische lymfat

[ Wed, Dec 14th 2011 ]: Market Wire

Datos finales de la Fase II que evalan REVLIMID y .. eucemia linfoctica crnica recurrente o resistente

[ Wed, Dec 14th 2011 ]: Market Wire

Premiere Cooperative Group in Adult Lymphoma Rese .. for Study in Second Most Common Lymphoma Subtype

[ Wed, Dec 14th 2011 ]: Market Wire

Salix Pharmaceuticals Announces NDA Submission fo .. emer for the Treatment of HIV-Associated Diarrhea

[ Wed, Dec 14th 2011 ]: Market Wire

Meta-analysis of Five Clinical Trials including C .. T Study Published in American Journal of Obstetri

[ Wed, Dec 14th 2011 ]: Market Wire

REVLIMID evaluado en combinacin con rituximab com .. pacientes con leucemia linfoctica crnica no trata

[ Wed, Dec 14th 2011 ]: Market Wire

Presentados en ASH los datos de un estudio de Fas .. en pacientes con mieloma indolente de alto riesgo

[ Wed, Dec 14th 2011 ]: Market Wire

OncoSec Medical Engages The Investor Relations Group

[ Wed, Dec 14th 2011 ]: Market Wire

Rsultats dfinitifs de laessai de phase II valuant .. ez les patients atteints de leucmie lymphocytaire

[ Wed, Dec 14th 2011 ]: Market Wire

Threshold Pharmaceuticals Announces Promising Pha .. Trial Results in Patients With Advanced Leukemias

[ Wed, Dec 14th 2011 ]: Market Wire

REVLIMID a t valu en combinaison avec le Rituxima .. ntiel destin aux patients atteints de leucmie lym

Tue, December 13, 2011

[ Tue, Dec 13th 2011 ]: Market Wire

ICU Medical's Tego Needlefree Connector Proves Mo .. ve Than Traditional Central Venous Catheter Locks

[ Tue, Dec 13th 2011 ]: Market Wire

The Law Firm of Levi & Korsinsky, LLP Announces I .. reaches of Fiduciary Duty by the Board of Synovis

[ Tue, Dec 13th 2011 ]: Market Wire

Pharmacyclics Announces Updated Results for BTK I .. eatment of Relapsed or Refractory Chronic Lymphoc

[ Tue, Dec 13th 2011 ]: Market Wire

Daxor Announces That the VA Medical Center in Was .. gton, D.C. Acquires BVA-100 Blood Volume Analyzer

[ Tue, Dec 13th 2011 ]: Market Wire

Rigrodsky & Long, P.A. Announces Investigation of .. ologies, Inc.as Sale to Baxter International Inc.

[ Tue, Dec 13th 2011 ]: Market Wire

Healthways to Update 2011 Financial Guidance after Market Close on December 20

[ Tue, Dec 13th 2011 ]: Market Wire

U.S. Physical Therapy to Present at the Oppenheimer 22nd Annual Healthcare Conference

[ Tue, Dec 13th 2011 ]: Market Wire

Seattle Genetics and Millennium Report Data from .. Brentuximab Vedotin) in Front-line Hodgkin Lympho

[ Tue, Dec 13th 2011 ]: Market Wire

St. Jude Medical Announces First Implant in Europ .. Studying Portico Transcatheter Aortic Heart Valve

[ Tue, Dec 13th 2011 ]: Market Wire

Die Europische Kommission erteilt Astellas Pharma .. zulassung zur Verwendung von DIFICLIRa" in der EU

[ Tue, Dec 13th 2011 ]: Market Wire

La Comisin Europea concede la autorizacin de mark .. Astellas Pharma Europe Ltd., para su uso en la UE

[ Tue, Dec 13th 2011 ]: Market Wire

PhotoMedex and Radiancy Complete Merger

[ Tue, Dec 13th 2011 ]: Market Wire

Bio-Path Holdingsa Initial Phase I Data in Leukem .. s That Its Neutral Lipid Delivery Technology Anti

[ Tue, Dec 13th 2011 ]: Market Wire

Thera Maxa" Cold and Flu Debuts in Times Square D .. ring the Height of the 2011 / 2012 Holiday Season

[ Tue, Dec 13th 2011 ]: Market Wire

A Change in Tides - Featured Research on Tenet Healthcare Corporation and Deluxe Corporation

[ Tue, Dec 13th 2011 ]: Market Wire

Direction of Market Influences - Report Highlight .. ceutical Industries Ltd (ADR) and Sanofi SA (ADR)

[ Tue, Dec 13th 2011 ]: Market Wire

Direction of Market Influences - Report Highlight .. uestcor Pharmaceuticals, Inc. and Perrigo Company

[ Tue, Dec 13th 2011 ]: Market Wire

A Potent and Safe Wound Care Agent

[ Tue, Dec 13th 2011 ]: Market Wire

GenVec President and Chief Executive Officer Announces Retirement

[ Tue, Dec 13th 2011 ]: Market Wire

Keryx Biopharmaceuticals Announces Phase 2 Data f .. e) in Hodgkin's Lymphoma Presented at ASH Meeting

Presentados en ASH los datos de un estudio de Fase III que evalan REVLIMID en pacientes con mieloma indolente de alto riesgo

//health-fitness.news-articles.net/content/2011/ .. ientes-con-mieloma-indolente-de-alto-riesgo.html

Published in Health and Fitness on Wednesday, December 14th 2011 at 3:22 GMT by Market Wire
^{🞛 This publication is a summary or evaluation of another publication}

BOUDRY, Suiza--([ BUSINESS WIRE ])--Celgene International Srl, filial de Celgene Corporation (NASDAQ: CELG), ha anunciado que los datos actualizados que evalan el tratamiento continuo con REVLIMID (lenalidomida) en pacientes con mieloma mltiple indolente asintomtico de alto riesgo, se han presentado en la 53 Reunin Anual de la American Society of Hematology. El estudio ha demostrado que el tratamiento previo con lenalidomida y dexametasona, seguido de lenalidomida continuada, ha retraso la aparicin de la enfermedad sintomtica y se ha demostrado una ventaja de supervivencia en comparacin con la observacin.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.